Sun Pharma reported robust FY25 performance with ₹85,462.9 Cr revenue & ₹10,929 Cr profit.

ESG strides include 21% Scope 1&2 emissions cut, 25% water reduction (exceeding targets), and 41% renewable energy.

R&D investments hit ₹3,250 Cr.

Operational integrity remained high, with only minor recalls and no significant compliance issues.